Artivion Finalizes Acquisition of Endospan to Enhance Aortic Disease Solutions

Artivion Completes Acquisition of Endospan Ltd.

ATLANTA, May 18, 2026 - Artivion, Inc. (NYSE: AORT), a frontrunner in cardiac and vascular surgery focused on treating aortic diseases, has officially closed its acquisition of Endospan Ltd., a company renowned for pioneering endovascular repair techniques for aortic arch diseases. This strategic move marks a significant advancement in Artivion's product offerings, particularly with the NEXUS® Aortic Arch System, which is designed to enhance surgical outcomes for patients facing complex aortic conditions.

The acquisition was financed through a $150 million delayed draw term loan, utilizing $135 million of those funds for the initial purchase price of Endospan. This acquisition comes with the potential for additional payments based on Endospan's commercial performance in the future, emphasizing Artivion's commitment to driving growth and innovation in the medical device sector.

In recent developments, the U.S. Food and Drug Administration (FDA) approved the premarket approval application for the NEXUS branched endovascular stent graft system in April 2026, further solidifying its market positioning. Since 2019, Artivion has exclusively distributed the NEXUS System across the EMEA region, establishing a strong foothold in the market prior to the acquisition.

Pat Mackin, Artivion's Chairman, President, and CEO, expressed enthusiasm about the acquisition, stating, "Bringing Endospan and its NEXUS system into our portfolio allows us to complete our leading position in the aortic arch market. As the sole company globally with a comprehensive array of aortic arch solutions, including AMDS and ARCEVO LSA, we are uniquely positioned for success in this crucial segment of healthcare." He further highlighted that the NEXUS is not a standalone product but a platform technology that will drive future innovations, positioning Artivion at the forefront of aortic arch care.

About Artivion, Inc.

Based in suburban Atlanta, Georgia, Artivion, Inc. is committed to developing advanced solutions for cardiac and vascular surgeons and their patients. The company’s diversified product lines include aortic stent grafts, surgical sealants, On-X mechanical heart valves, and human tissues for cardiac and vascular applications. With an operational presence in over 100 countries, Artivion continues to make strides in improving patient health outcomes globally. For more information, please visit Artivion's website.

About Endospan Ltd.

Endospan, based in Herzliya, Israel, has made notable advancements in the endovascular repair of aortic arch diseases, serving a patient demographic historically underserved by traditional surgical approaches. The NEXUS Stent Graft System holds the distinction of being the first endovascular off-the-shelf system to treat Aortic Arch Disease effectively. Patients with dilative lesions in or near the aortic arch have often faced the challenges of invasive open-chest surgeries; Endospan's innovative solutions aim to change that landscape. More details about Endospan and its product offerings can be found on its official website.

Overall, the convergence of these two companies aims to address significant health challenges and improve the quality of life for patients globally, paving the way for future advancements in vascular surgery and innovation.